The negative impact of cytomegalovirus (CMV) infection on transplant outcomes warrants
efforts toward improving its prevention, diagnosis, and treatment. During the last 2 decades …

Cytomegalovirus (CMV) is a leading opportunistic infection in immune compromised
patients, including allogeneic hematopoietic stem cell (HSCT) or solid organ transplant …

Cytomegalovirus (CMV) is a ubiquitous herpes virus that infects the majority of humans (1).
The seroprevalence rates of CMV ranges from 30–97%(2, 3). Primary infection manifests as …

Background Cytomegalovirus (CMV) infection is a leading cause of illness and death in
patients who have undergone allogeneic hematopoietic-cell transplantation. Available …

Patients treated with allogeneic hematopoietic cell transplantation (HCT) are at risk of
cytomegalovirus (CMV) reactivation and disease, which results in increased morbidity and …

Human cytomegalovirus (HCMV) is responsible for life-threatening infections in
immunocompromised individuals and can cause serious congenital malformations …

The recent approval of letermovir marks a new era of therapy for human cytomegalovirus
(HCMV) infections, particularly for the prevention of HCMV disease in hematopoietic stem …

Treatment options for drug-resistant cytomegalovirus (CMV) are limited. Letermovir is a
novel antiviral recently approved for CMV prophylaxis following hematopoietic cell …

Cytomegalovirus (CMV) infection remains a significant cause of morbidity and mortality in
transplant recipients. Letermovir (AIC 246), is a novel anti‐HCMV drug in development …

The prevention and treatment of human cytomegalovirus (HCMV) infections is based on the
use of antiviral agents that currently target the viral DNA polymerase and that may cause …